# Monoclonal Antibodies Related to Intestine Diseases

## Inflammatory Bowel Diseases

| Name | Type/Source | Target | Use |
|--|--|--|--|
| Abrilumab | mab/human | integrin α₄ β₇ | IBD, UC, CD |
| Actoxumab | mab/human | _Clostridioides difficile_ | _Clostridioides difficile_ colitis |
| Adalimumab | mab/human | TNF-α | CD (+) |
| Bezlotoxumab | mab/human | integrin α₄ β₇ | IBD, UC, CD |
| Brazikumab | mab/human | IL-23 | CD |
| Briakinumab | mab/human | IL-12, IL-23 | IBD (+) |
| Certolizumab pegol | Fab'/humanized | TNF-α | CD (+) |
| Efungumab | scFv/human | Hsp90 | invasive _Candida_ infection |
| Eldelumab | mab/human | CXCL10 (IP-10) | CD, UC |
| Etrolizumab | mab/humanized | integrin β₇ | IBD |
| Fontolizumab | mab/humanized | IFN-γ | CD etc. |
| Golimumab | mab/human | TNF-α | UC (+) |
| Infliximab | mab/chimeric | TNF-α | CD, UC (+) |
| Mirikizumab | mab/humanized | IL-23 | UC |
| Natalizumab | mab/humanized | integrin α₄ | CD (+) |
| Pateclizumab | mab/humanized | LT-α (lymphotoxin-alpha) | TNF |
| Priliximab | mab/chimeric | CD4 | CD (+) |
| Ravagalimab | mab/humanized | CD40 | CD |
| Risankizumab | mab/humanized | IL-23A | CD (+) |
| Ontamalimab (SHP647) | -/human | MAdCAM (mucosal addressin cell adhesion molecule) | CD |
| Urtoxazumab | mab/humanized | _Escherichia coli_ | diarrhoea caused by _E. coli_ |
| Ustekinumab | mab/human | IL-12, IL-23 | CD (+) |
| Vedolizumab | mab/humanized | integrin α₄ β₇ | CD, UC |
| Visilizumab | mab/humanized | CD3 | CD, UC |


> Type:  
> **mab** - whole monoclonal antibody  
> **Fab'** - fragment, antigen-binding, including hinge region (one arm)  
> **scFv** - single-chain variable fragment
>   
> Use:  
> **IBD** - Inflammatory Bowel Disease  
> **UC** - ulcerative colitis  
> **CD** - Crohn's disease
>
> (+) - and others

> [List of monoclonal antibodies](https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies)

## General Inflammatory/Autoimmune Diseases

| Name | Type/Source | Target | Use |
|--|--|--|--|
| Bertilimumab | mab/human | CCL11 (eotaxin-1) | severe allergic disorders |
| Besilesomab | mab/mouse | CEA (Carcinoembryonic antigen)-related antigen | inflammatory lesions and metastases (detection) |
| Carlumab | mab/human | MCP-1 | oncology/immune indications |
| Cedelizumab | mab/humanized | CD4 | autoimmune diseases |
| Fanolesomab | mab/mouse | CD15 | appendictis (diagnosis) |
| Ixekizumab | mab/humanized | IL-17A | autoimmune diseases |
| Letolizumab | scFv/humanized | TRAP (TNF-related activation protein) | inflammatory diseases |
| Lulizumab pegol | mab/humanized | CD28 | autoimmune diseases |
| Odulimomab | mab/mouse | LFA-1 (CD11a) | immunological diseases |
| Ozoralizumab | mab/humanized | TNF-α | inflammation |
| Placulumab | mab/human | TNF-α | inflammatory diseases |
| Reslizumab | mab/humanized | IL-5 | inflammations of gastrointestinal tract |
| Rituximab | mab/chimeric | CD20 | some autoimmune disorders |
| Talizumab | mab/humanized | IgE | allergic reaction |
| Teneliximab | mab/chimeric | CD40 | autoimmune diseases |
| Tibulizumab | mab/humanized | BAFF (B-cell activating factor) | autoimmune disorders |
| Tildrakizumab  | mab/humanized | IL-23 | immunologically mediated inflammatory disorders |
| Vepalimomab | mab/mouse | AOC3 (VAP-1) | inflammation |
| Vobarilizumab | scFv/humanized | IL-6 receptor | inflammatory autoimmune diseases |
